<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:11:32Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10619035" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10619035</identifier>
        <datestamp>2023-11-02</datestamp>
        <setSpec>bmjdrc</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMJ Open Diabetes Res Care</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMJ Open Diabetes Res Care</journal-id>
              <journal-id journal-id-type="hwp">bmjdrc</journal-id>
              <journal-id journal-id-type="publisher-id">bmjdrc</journal-id>
              <journal-title-group>
                <journal-title>BMJ Open Diabetes Research &amp; Care</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2052-4897</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10619035</article-id>
              <article-id pub-id-type="pmcid">PMC10619035</article-id>
              <article-id pub-id-type="pmc-uid">10619035</article-id>
              <article-id pub-id-type="pmid">37907279</article-id>
              <article-id pub-id-type="pmid">37907279</article-id>
              <article-id pub-id-type="publisher-id">bmjdrc-2023-003585</article-id>
              <article-id pub-id-type="doi">10.1136/bmjdrc-2023-003585</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Epidemiology/Health services research</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                  <subject>1867</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Can earlier biomarker measurements explain a treatment effect on diabetes incidence? A robust comparison of five surrogate markers</article-title>
              </title-group>
              <contrib-group>
                <contrib id="author-108920084" contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7288-1009</contrib-id>
                  <name>
                    <surname>Parast</surname>
                    <given-names>Layla</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-108920105" contrib-type="author">
                  <name>
                    <surname>Tian</surname>
                    <given-names>Lu</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-108920106" contrib-type="author">
                  <name>
                    <surname>Cai</surname>
                    <given-names>Tianxi</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib id="author-5029139" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1245-665X</contrib-id>
                  <name>
                    <surname>Palaniappan</surname>
                    <given-names>Latha P</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label><institution specific-use="Ringgold_12330">The University of Texas at Austin</institution>, <addr-line content-type="city">Austin</addr-line>, <addr-line content-type="state">Texas</addr-line>, <country>USA</country></aff>
              <aff id="aff2"><label>2</label><institution content-type="department">Department of Biomedical Data Science</institution>, <institution specific-use="Ringgold_6429">Stanford University</institution>, <addr-line content-type="city">Stanford</addr-line>, <addr-line content-type="state">California</addr-line>, <country>USA</country></aff>
              <aff id="aff3"><label>3</label><institution content-type="department">Department of Biomedical Informatics</institution>, <institution specific-use="Ringgold_1811">Harvard Medical School</institution>, <addr-line content-type="city">Boston</addr-line>, <addr-line content-type="state">Massachusetts</addr-line>, <country>USA</country></aff>
              <aff id="aff4"><label>4</label><institution content-type="department">Department of Biostatistics</institution>, <institution>Harvard TH Chan School of Public Health</institution>, <addr-line content-type="city">Boston</addr-line>, <addr-line content-type="state">Massachusetts</addr-line>, <country>USA</country></aff>
              <aff id="aff5"><label>5</label><institution content-type="department">Department of Medicine</institution>, <institution specific-use="Ringgold_10624">Stanford University School of Medicine</institution>, <addr-line content-type="city">Stanford</addr-line>, <addr-line content-type="state">California</addr-line>, <country>USA</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Dr Layla Parast; <email>parast@austin.utexas.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>31</day>
                <month>10</month>
                <year>2023</year>
              </pub-date>
              <volume>11</volume>
              <issue>5</issue>
              <elocation-id>e003585</elocation-id>
              <history>
                <date date-type="received">
                  <day>12</day>
                  <month>6</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>07</day>
                  <month>10</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <ali:free_to_read/>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense" start_date="2023-10-31">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="bmjdrc-2023-003585.pdf"/>
              <abstract>
                <sec>
                  <title>Introduction</title>
                  <p>We measured and compared five individual surrogate markers—change from baseline to 1 year after randomization in hemoglobin A1c (HbA1c), fasting glucose, 2-hour postchallenge glucose, triglyceride–glucose index (TyG) index, and homeostatic model assessment of insulin resistance (HOMA-IR)—in terms of their ability to explain a treatment effect on reducing the risk of type 2 diabetes mellitus at 2, 3, and 4 years after treatment initiation.</p>
                </sec>
                <sec>
                  <title>Research design and methods</title>
                  <p>Study participants were from the Diabetes Prevention Program study, randomly assigned to either a lifestyle intervention (n=1023) or placebo (n=1030). The surrogate markers were measured at baseline and 1 year, and diabetes incidence was examined at 2, 3, and 4 years postrandomization. Surrogacy was evaluated using a robust model-free estimate of the proportion of treatment effect explained (PTE) by the surrogate marker.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>Across all time points, change in fasting glucose and HOMA-IR explained higher proportions of the treatment effect than 2-hour glucose, TyG index, or HbA1c. For example, at 2 years, glucose explained the highest (80.1%) proportion of the treatment effect, followed by HOMA-IR (77.7%), 2-hour glucose (76.2%), and HbA1c (74.6%); the TyG index explained the smallest (70.3%) proportion.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>These data suggest that, of the five examined surrogate markers, glucose and HOMA-IR were the superior surrogate markers in terms of PTE, compared with 2-hour glucose, HbA1c, and TyG index.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>biomarkers</kwd>
                <kwd>diabetes mellitus, type 2</kwd>
                <kwd>treatment outcome</kwd>
                <kwd>biostatistics</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id>
                      <institution>National Institutes of Health</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R01DK118354</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <boxed-text id="BX1" position="float">
              <sec>
                <title>WHAT IS ALREADY KNOWN ON THIS TOPIC</title>
                <list list-type="bullet">
                  <list-item>
                    <p>In the US Food and Drug Administration’s current table of surrogate markers/endpoints that have been used as the basis for drug approval or licensure, the only surrogate marker listed for type 2 diabetes is serum hemoglobin A1c (HbA1c); however, in the clinical literature, it is well known that there exist other potential surrogate markers for diabetes, such as fasting plasma glucose.</p>
                  </list-item>
                </list>
              </sec>
              <sec>
                <title>WHAT THIS STUDY ADDS</title>
                <list list-type="bullet">
                  <list-item>
                    <p>This study compares five surrogate markers for diabetes—HbA1c, fasting glucose, 2-hour postchallenge glucose, triglyceride–glucose index, and homeostatic model assessment of insulin resistance—in terms of their ability to explain a treatment effect on reducing the risk of type 2 diabetes mellitus at 2, 3, and 4 years after treatment initiation.</p>
                  </list-item>
                  <list-item>
                    <p>This study is the first to compare these five surrogate markers using a robust model-free approach.</p>
                  </list-item>
                </list>
              </sec>
              <sec>
                <title>HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY</title>
                <list list-type="bullet">
                  <list-item>
                    <p>These results provide insight into the complex relationship between the change in these markers and diabetes incidence that may be useful in the design and analysis of future studies on diabetes prevention.</p>
                  </list-item>
                </list>
              </sec>
            </boxed-text>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>Clinical studies examining interventions to prevent or delay type 2 diabetes mellitus (diabetes) typically require long follow-up of participants in order to have sufficient power to detect an intervention or treatment effect. In such studies, the availability of a surrogate marker that can be used in place of the primary outcome to test for a treatment effect has the potential to decrease study time and costs, as well as patient burden.</p>
              <p>The Accelerated Approval Program of the US Food and Drug Administration (FDA) allows for drugs to be approved based on demonstrated effectiveness on a surrogate marker.<xref rid="R1" ref-type="bibr">1</xref> While this program allows for effective drugs to be made available to patients in need sooner, the requirements for what constitutes a surrogate marker are not clear. The FDA describes a surrogate marker as an intermediate endpoint that measures “a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on irreversible morbidity and mortality.”<xref rid="R1" ref-type="bibr">1</xref> This definition and program more generally has been widely criticized for potentially allowing drugs to be approved and marketed without demonstrated effectiveness on the primary clinical outcome.<xref rid="R2" ref-type="bibr">2</xref> A recent controversial example of this is the approval of aducanumab (Aduhelm) for Alzheimer’s disease, which showed effectiveness with respect to reducing amyloid plaques in the brain even though the theory linking amyloid clearance with slowing cognitive and functional decline is not completely clear.<xref rid="R3" ref-type="bibr">3</xref></p>
              <p>In the FDA’s current table of surrogate markers/endpoints that have been used as the basis for drug approval or licensure, the only surrogate marker listed for type 2 diabetes is serum hemoglobin A1c (HbA1c).<xref rid="R4" ref-type="bibr">4</xref> However, in the clinical literature, it is well known that there exist other potential surrogate markers for diabetes, such as fasting plasma glucose.<xref rid="R5" ref-type="bibr">5 6</xref> More recent surrogate markers include the triglyceride–glucose index (TyG) and the homeostatic model assessment of insulin resistance (HOMA-IR), an indirect marker of insulin resistance which has been widely used in practice, both of which have been shown to be predictive of diabetes incidence.<xref rid="R7" ref-type="bibr">7–9</xref></p>
              <p>The statistical validation of surrogate markers is complex and there is currently no agreement in the statistical literature on a single optimal way to validate a surrogate.<xref rid="R10" ref-type="bibr">10</xref> The most commonly used measure of surrogate validity in practice is the proportion of the treatment effect on the primary outcome that is explained by the surrogate marker (proportion of treatment effect explained, PTE).<xref rid="R11" ref-type="bibr">11–13</xref> While many other statistical measures have been proposed to evaluate surrogates, the single number summary of the PTE as well as its intuitive interpretation have led to the widespread use and acceptance of the PTE as a measure of surrogate strength.<xref rid="R14" ref-type="bibr">14–18</xref> For example, since the PTE is a proportion, a value close to 1.0 reflects a surrogate that can explain almost all of the treatment effects on the primary outcome, while a value close to 0 reflects a surrogate that essentially cannot explain any of the treatment effect. Although there is no agreed-upon single threshold for what constitutes a “good” surrogate marker, previous work has proposed that PTE estimates above 0.90 and/or PTE estimates with a 95% CI whose lower bound is greater than 0.50 or 0.75 are indicative of a reasonably strong surrogate marker.<xref rid="R19" ref-type="bibr">19</xref> A high PTE ensures that evaluating the treatment effect on the surrogate marker is likely to have a satisfactory statistical power and provide a good bound approximating the treatment effect on the primary outcome. A major criticism of the PTE is that its statistical inference relies on correct parametric model specification (eg, linear regressions) which must accurately capture the complex relationship between the treatment, the surrogate marker, and the primary outcome.<xref rid="R19" ref-type="bibr">19–21</xref> Fortunately, recent work has developed a non-parametric model-free estimation approach to PTE that does not require any parametric specification and has been shown to perform well when the true relationship between these variables is complex.<xref rid="R21" ref-type="bibr">21–23</xref></p>
              <p>In this study, we construct a non-parametric estimate of the PTE using new statistical techniques without restrictive model assumptions. The model-free PTE estimate allows us to robustly measure and compare five surrogate markers (HbA1c, fasting glucose, 2-hour postchallenge glucose, TyG, and HOMA-IR) for diabetes diagnosis among patients at high risk for diabetes using secondary data from the Diabetes Prevention Program (DPP).</p>
            </sec>
            <sec id="s2">
              <title>Subjects, materials, and methods</title>
              <sec id="s2-1">
                <title>DPP and participants</title>
                <p>The DPP was a randomized, double-blind, placebo-controlled clinical trial designed to test interventions to prevent or delay the development of type 2 diabetes in high-risk adults with impaired glucose tolerance. Participants were randomly assigned to four groups: placebo, lifestyle intervention, metformin (850 mg two times per day), and troglitazone. Detailed study design and primary study results are reported elsewhere.<xref rid="R24" ref-type="bibr">24 25</xref> This secondary data analysis is based on publicly available data through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Central Repository.<xref rid="R26" ref-type="bibr">26</xref> Only clinics with IRB approval to distribute their data to the repository are included in the data release; this constitutes 3665 participants out of the original 3819 DPP participants. In this study, we specifically examined the treatment effect of the lifestyle intervention compared with the placebo group. One participant missing HbA1c at baseline was excluded from the analysis. Our final analytic data set was composed of 1023 participants assigned to the lifestyle intervention and 1030 participants assigned to placebo.</p>
              </sec>
              <sec id="s2-2">
                <title>Primary outcome</title>
                <p>The primary outcome in the DPP study was time to a type 2 diabetes diagnosis, which was defined by the DPP protocol based on either fasting glucose or 2-hour postchallenge glucose: fasting glucose ≥140 mg/dL or 2-hour postchallenge glucose ≥200 mg/dL (for visits through June 23, 1997), and fasting glucose ≥126 mg/dL or 2-hour postchallenge glucose ≥200 mg/dL (for visits from June 24, 1997 through April 1, 2000). Fasting glucose was measured at annual and midyear visits, while an oral glucose tolerance test was completed only at annual visits. A participant with an elevated glucose level at either an annual visit or a midyear visit would then have a follow-up confirmation visit within 6 weeks, and if the same glucose level was still elevated the participants would be diagnosed as having achieved the primary outcome of type 2 diabetes.</p>
              </sec>
              <sec id="s2-3">
                <title>Surrogate markers</title>
                <p>Five surrogate markers were examined: HbA1c, fasting glucose, 2-hour postchallenge glucose, TyG index, and the homeostatic model assessment for insulin resistance (HOMA-IR). The TyG index was calculated as: ln [fasting serum triglyceride (mg/dL)×FPG (mg/dL)/2].<xref rid="R9" ref-type="bibr">9</xref> The HOMA-IR level was calculated as: [fasting serum insulin (μU/mL)×FPG (mg/dL)/405].<xref rid="R8" ref-type="bibr">8</xref> The change in each surrogate marker was defined as the change in the biomarker from baseline to 1-year postrandomization.</p>
              </sec>
              <sec id="s2-4">
                <title>Statistical methods</title>
                <p>The cumulative incidence by group was examined using the Kaplan-Meier estimate.<xref rid="R27" ref-type="bibr">27</xref> Patients who died within 4 years from randomization (n=9) were censored at the time of death. The distributions of the change in each surrogate from randomization to 1 year among participants still under observation at 1 year were descriptively examined using stratified boxplots. Each surrogate marker was evaluated by calculating the proportion of the treatment effect on the primary outcome that was explained (PTE) by the treatment effect on the surrogate information at 1-year postrandomization. The treatment effect on the primary outcome was quantified as the difference in diabetes cumulative incidence at a specific time, <italic toggle="yes">t</italic>, where <italic toggle="yes">t</italic>=2 years, 3 years, and 4 years were examined. That is, the treatment effect at time <italic toggle="yes">t</italic>, denoted as <inline-formula><mml:math id="M1" overflow="scroll"><mml:mo>∆</mml:mo><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula>, was equal to <inline-formula><mml:math id="M2" overflow="scroll"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>T</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup><mml:mo>&gt;</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>T</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>b</mml:mi><mml:mi>o</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup><mml:mo>&gt;</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>, where <inline-formula><mml:math id="M3" overflow="scroll"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>T</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>R</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> is the time from baseline to diabetes diagnosis under intervention <italic toggle="yes">R</italic>; this is illustrated in <xref rid="F1" ref-type="fig">figure 1</xref>, where <inline-formula><mml:math id="M4" overflow="scroll"><mml:mo>∆</mml:mo><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> is the distance between the two treatment group curves at each specific time t. The PTE is defined as the ratio between the portion of the treatment effect that is explained by the surrogate versus the total treatment effect on the primary outcome. Specifically, <inline-formula><mml:math id="M5" overflow="scroll"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>P</mml:mi><mml:mi>T</mml:mi><mml:mi>E</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>, where <inline-formula><mml:math id="M6" overflow="scroll"><mml:msub><mml:mrow><mml:mo>∆</mml:mo></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula> denotes the residual treatment effect on the primary outcome after the treatment effect on the surrogate marker is removed.<xref rid="R13" ref-type="bibr">13</xref> This is parallel to the direct and indirect effects framework in causal inference.<xref rid="R14" ref-type="bibr">14</xref> Both <inline-formula><mml:math id="M7" overflow="scroll"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="M8" overflow="scroll"><mml:msub><mml:mrow><mml:mo>∆</mml:mo></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula> are estimated non-parametrically using robust kernel-smoothing methods that do not require any parametric modeling.<xref rid="R22" ref-type="bibr">22</xref> Perturbation resampling, a variant of bootstrap, was used to construct 95% CIs.<xref rid="R28" ref-type="bibr">28 29</xref></p>
                <fig position="float" id="F1">
                  <label>Figure 1</label>
                  <caption>
                    <p>Cumulative incidence by treatment group, with dashed lines at <italic toggle="yes">t</italic>=2 years, <italic toggle="yes">t</italic>=3 years, and <italic toggle="yes">t</italic>=4 years; the treatment effect at time <italic toggle="yes">t,</italic>
<inline-formula><mml:math id="M9" overflow="scroll"><mml:mo>∆</mml:mo><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula>, is equal to the distance between the two treatment group curves at each specific time <italic toggle="yes">t</italic>.</p>
                  </caption>
                  <graphic xlink:href="bmjdrc-2023-003585f01" position="float"/>
                </fig>
                <p>Importantly, this statistical approach evaluates a surrogate marker by considering the surrogate marker information at 1 year to be a <italic toggle="yes">combination</italic> of (1) the 1-year change in the surrogate marker for those who had not yet been diagnosed with diabetes and (2) diabetes incidence if diabetes was diagnosed before 1 year. Alternative methods that either ignore diabetes incidence before 1 year or evaluate the surrogacy only among those who were not diagnosed with diabetes before 1 year are not appropriate. Our approach incorporates all information about diabetes incidence available at the time of surrogate marker measurement in order to quantify the overall strength of the surrogate information at 1 year with respect to predicting the treatment effect at time <italic toggle="yes">t</italic>. This approach also allows us to calculate the incremental value (IV) of the surrogate marker alone, that is, providing an estimate of the proportion of the total treatment effect on the primary endpoint explained by only the surrogate marker.<xref rid="R22" ref-type="bibr">22</xref> For each surrogate marker, we calculate (1) the overall PTE of the surrogate information and (2) the IV of the marker measurement alone.</p>
                <p>Statistical analyses were performed using R V.4.2.1 and using the R package Rsurrogate.<xref rid="R30" ref-type="bibr">30</xref> Throughout, statistical inference is based on 95% CIs rather than p values.</p>
              </sec>
              <sec id="s2-5">
                <title>Data and resource availability</title>
                <p>The DPP study data used in this analysis are publicly available through the NIDDK Central Repository (<ext-link xlink:href="https://repository.niddk.nih.gov/studies/dpp/" ext-link-type="uri">https://repository.niddk.nih.gov/studies/dpp/</ext-link>) upon establishment of data use agreement.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s3">
              <title>Results</title>
              <p>Overall, 67.4% of the participants were female, half were 50 or older, 38% had a body mass index of 35 or higher, and the majority (56.8%) were white (<xref rid="T1" ref-type="table">table 1</xref>). At baseline, the participants had a mean HbA1c of 5.9, a mean fasting glucose of 107.2 mg/dL, a mean 2-hour glucose of 164.5, a mean TyG index of 8.9, and a mean HOMA-IR of 7.0. Participant characteristics were similar across the treatment groups, which is expected given randomization. Descriptively, the distribution of the change in each of the five markers differed by treatment group (<xref rid="F2" ref-type="fig">figure 2</xref>).</p>
              <fig position="float" id="F2">
                <label>Figure 2</label>
                <caption>
                  <p>Distribution of marker changes from randomization to 1 year by treatment group, among participants still under observation at 1 year. HbA1c, hemoglobin A1c; HOMA-IR, homeostatic model assessment of insulin resistance; TyG, triglyceride–glucose index.</p>
                </caption>
                <graphic xlink:href="bmjdrc-2023-003585f02" position="float"/>
              </fig>
              <table-wrap position="float" id="T1">
                <label>Table 1</label>
                <caption>
                  <p>Participant characteristics overall and by treatment group</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <td align="left" valign="bottom" rowspan="1" colspan="1"/>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Overall (N=2053)</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Placebo (n=1030)</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Lifestyle intervention (n=1023)</td>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Age, n (%)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1"> &lt;40</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">317 (15.4)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">151 (14.7)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">166 (16.2)</td>
                    </tr>
                    <tr>
                      <td align="char" char="ndash" valign="top" rowspan="1" colspan="1"> 40–44</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">303 (14.8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">147 (14.3)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">156 (15.2)</td>
                    </tr>
                    <tr>
                      <td align="char" char="ndash" valign="top" rowspan="1" colspan="1"> 45–49</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">425 (20.7)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">231 (22.4)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">194 (19)</td>
                    </tr>
                    <tr>
                      <td align="char" char="ndash" valign="top" rowspan="1" colspan="1"> 50–54</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">315 (15.3)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">167 (16.2)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">148 (14.5)</td>
                    </tr>
                    <tr>
                      <td align="char" char="ndash" valign="top" rowspan="1" colspan="1"> 55–59</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">266 (13)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">134 (13)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">132 (12.9)</td>
                    </tr>
                    <tr>
                      <td align="char" char="ndash" valign="top" rowspan="1" colspan="1"> 60–64</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">203 (9.9)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">100 (9.7)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">103 (10.1)</td>
                    </tr>
                    <tr>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1"> 65 and older</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">224 (10.9)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">100 (9.7)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">124 (12.1)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Sex, n (%)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Male</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">670 (32.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">331 (32.1)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">339 (33.1)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Female</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">1383 (67.4)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">699 (67.9)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">684 (66.9)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Body mass index, n (%)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1"> &lt;30 kg/m<sup>2</sup></td>
                      <td align="left" valign="top" rowspan="1" colspan="1">663 (32.3)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">326 (31.7)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">337 (32.9)</td>
                    </tr>
                    <tr>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1"> ≥30–&lt;35 kg/m<sup>2</sup></td>
                      <td align="left" valign="top" rowspan="1" colspan="1">610 (29.7)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">297 (28.8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">313 (30.6)</td>
                    </tr>
                    <tr>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1"> ≥35 kg/m<sup>2</sup></td>
                      <td align="left" valign="top" rowspan="1" colspan="1">780 (38)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">407 (39.5)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">373 (36.5)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Race/ethnicity, n (%)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> White</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">1166 (56.8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">586 (56.9)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">580 (56.7)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Black</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">423 (20.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">219 (21.3)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">204 (19.9)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Hispanic</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">345 (16.8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">168 (16.3)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">177 (17.3)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Other</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">119 (5.8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">57 (5.5)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">62 (6.1)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Baseline HbA1c (%), mean (SD)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">5.9 (0.5)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">5.9 (0.5)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">5.9 (0.5)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Baseline fasting glucose (mg/dL), mean (SD)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">107.2 (7.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">107.4 (7.8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">107 (7.5)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Baseline 2-hour glucose (mg/dL), mean (SD)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">164.5 (17)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">164.6 (17.2)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">164.4 (16.8)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Baseline TyG index, mean (SD)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">8.9 (0.5)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">9 (0.5)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">8.9 (0.5)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Baseline HOMA-IR, mean (SD)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">7 (4.2)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">7.1 (4.1)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">7 (4.3)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" colspan="4" rowspan="1">Postbaseline characteristics</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Cumulative diabetes incidence at 1 year, %</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">13.0</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">18.7</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">7.2</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Cumulative diabetes incidence at 2 years, %</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">21.4</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">28.9</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">14.0</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Cumulative diabetes incidence at 3 years, %</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">28.3</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">36.2</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">20.5</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> HbA1c at 1 year (%), mean (SD)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">5.9 (0.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">6 (0.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">5.8 (0.5)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Fasting glucose at 1 year (mg/dL), mean (SD)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">104.6 (13.8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">107.3 (13.8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">101.9 (13.2)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> 2-hour glucose at 1 year (mg/dL), mean (SD)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">150.3 (38.4)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">157.8 (39.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">142.6 (35.5)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> TyG at 1 year, mean (SD)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">8.8 (0.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">8.9 (0.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">8.7 (0.6)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> HOMA-IR at 1 year, mean (SD)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">6.5 (4.8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">7.4 (5)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">5.6 (4.4)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="T1_FN1">
                    <p>Cumulative incidence was estimated using the Kaplan-Meier estimator; surrogate marker measurements postbaseline are shown among those still under observation at 1 year.</p>
                  </fn>
                  <fn id="T1_FN2">
                    <p>HbA1c, hemoglobin A1c; HOMA-IR, homeostatic model assessment of insulin resistance; TyG, triglyceride–glucose index.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>The cumulative incidence of diabetes was lower among patients assigned to lifestyle intervention compared with those assigned to placebo, which is consistent with the primary DPP study results (<xref rid="T1" ref-type="table">table 1</xref> and <xref rid="F1" ref-type="fig">figure 1</xref>). The estimated treatment effect on diabetes incidence, <inline-formula><mml:math id="M10" overflow="scroll"><mml:mo>∆</mml:mo><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula>, at 2 years was 0.113 (95% CI 0.084, 0.139), at 3 years was 0.149 (95% CI 0.108, 0.189), and at 4 years was 0.158 (95% CI 0.104, 0.217).</p>
              <p><xref rid="T2" ref-type="table">Table 2</xref> shows the estimated PTE and IV for each surrogate marker at each examined time point, along with 95% CIs. For all time points, glucose and HOMA-IR explained higher proportions of the treatment effect than 2-hour glucose, TyG, or HbA1c. At 2 years, glucose explained the highest (80.1%) proportion of the treatment effect (PTE=0.801, 95% CI 0.639, 1.005), followed by HOMA-IR (PTE=0.777, 95% CI 0.605, 0.984), 2-hour glucose (PTE=0.762, 95% CI 0.621, 0.934), and HbA1c (PTE=0.746, 95% CI 0.587, 0.940). The TyG index explained the smallest (70.3%) proportion (PTE=0.703, 95% CI 0.567, 0.864). At 3 years, glucose continued to explain the highest proportion (71.2%), but HbA1c explains the smallest (52.9%), with all marker PTE decreasing as the time point is farther from 1 year. At 4 years, HOMA-IR explained the highest (62.3%) proportion of the treatment effect, followed by glucose (61.4%), 2-hour glucose (57.5%), TyG (55.8%), and HbA1c (43.2%).</p>
              <table-wrap position="float" id="T2">
                <label>Table 2</label>
                <caption>
                  <p>Proportion of treatment effect explained and the incremental value of each surrogate marker</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <td align="left" valign="bottom" colspan="4" rowspan="1">PTE by each surrogate marker</td>
                    </tr>
                    <tr>
                      <td align="left" valign="bottom" rowspan="1" colspan="1"/>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">PTE 2 years<break/>Estimate (95% CI)</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">PTE 3 years<break/>Estimate (95% CI)</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">PTE 4 years<break/>Estimate (95% CI)</td>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">HbA1c</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.746 (0.587, 0.940)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.529 (0.367, 0.700)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.432 (0.261, 0.642)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Fasting glucose</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.801 (0.639, 1.005)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.712 (0.546, 0.940)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.614 (0.426, 0.978)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">2-hour glucose</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.762 (0.621, 0.934)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.645 (0.494, 0.842)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.575 (0.388, 0.915)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">TyG</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.703 (0.567, 0.864)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.624 (0.469, 0.826)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.558 (0.389, 0.807)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">HOMA-IR</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.777 (0.605, 0.984)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.689 (0.523, 0.920)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.623 (0.422, 0.965)</td>
                    </tr>
                  </tbody>
                </table>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <td align="left" valign="bottom" colspan="4" rowspan="1">IV of each surrogate marker</td>
                    </tr>
                    <tr>
                      <td align="left" valign="bottom" rowspan="1" colspan="1"/>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">IV 2 years<break/>Estimate (95% CI)</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">IV 3 years<break/>Estimate (95% CI)</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">IV 4 years<break/>Estimate (95% CI)</td>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">HbA1c</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.069 (0, 0.156)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.049 (−0.058, 0.145)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.016 (−0.137, 0.132)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Fasting glucose</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.124 (0.059, 0.224)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.232 (0.129, 0.374)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.198 (0.083, 0.359)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">2-hour glucose</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.085 (0.035, 0.142)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.165 (0.088, 0.262)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.160 (0.045, 0.314)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">TyG</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.026 (−0.009, 0.074)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.144 (0.066, 0.237)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.143 (0.030, 0.278)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">HOMA-IR</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.100 (0.037, 0.195)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.209 (0.116, 0.350)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.208 (0.081, 0.412)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="T2_FN1">
                    <p>HbA1c, hemoglobin A1c; HOMA-IR, the homeostatic model assessment for insulin resistance; IV, incremental value; PTE, proportion of treatment effect explained; TyG, triglyceride–glucose index.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>Patterns for the IV paralleled the PTE, as expected, with IV estimates for the five markers ranging from 0.069 to 0.124 at 2 years, from 0.049 to 0.232 at 3 years, and from 0.016 to 0.208 at 4 years. The 95% CIs for the IV of fasting glucose, 2-hour glucose, and HOMA-IR for all time points excluded 0, thus providing evidence that the IV of these markers is greater than 0. In contrast, the 95% CIs for the IV of HbA1c included 0 for all time points. For the TyG index, there was evidence of positive IV for <inline-formula><mml:math id="M11" overflow="scroll"><mml:mi>t</mml:mi></mml:math></inline-formula>=3 and <italic toggle="yes">t</italic>=4 years, but not for <italic toggle="yes">t</italic>=2 years.</p>
            </sec>
            <sec sec-type="discussion" id="s4">
              <title>Discussion</title>
              <p>The results demonstrate that, of the five examined surrogate markers, fasting glucose and HOMA-IR explained the largest proportions of the treatment effect when comparing lifestyle intervention with placebo. The TyG index and HbA1c were the weakest surrogate markers in terms of the proportion of the treatment effect that could be explained. The PTE for all markers decreased for later values of <italic toggle="yes">t</italic>, which is generally expected, as the treatment effect is generally more difficult to capture as the length of time between the surrogate marker measurement and the treatment effect measurement increases.</p>
              <p>While we focus on the surrogate information at 1 year, our approach could similarly be used to examine the PTE of surrogate information at 2 years, when <italic toggle="yes">t</italic>=3 years or <italic toggle="yes">t</italic>=4 years. We conducted such an analysis as a sensitivity analysis (results not shown) examining the average changes in the surrogate markers during the first 2 years, investigating the PTE and IV at time points after 2 years only (3 years and 4 years). The general patterns were similar to the main results, where fasting glucose, HOMA-IR, and 2-hour glucose appear to have higher surrogacy than HbA1c and the TyG index.</p>
              <p>Previous work examining TyG and HOMA-IR has demonstrated that these markers are independently predictive of diabetes incidence. Park <italic toggle="yes">et al</italic><xref rid="R8" ref-type="bibr">8</xref> showed that the TyG index was significantly better than HOMA-IR in terms of the area under the time-dependent receiver operating characteristic curve (AUC). Importantly, while prediction accuracy information is useful, estimates reflecting good prediction accuracy do not necessarily translate to a measurement being a good surrogate marker. For example, in Park <italic toggle="yes">et al</italic>,<xref rid="R8" ref-type="bibr">8</xref> the AUC for the TyG index in predicting diabetes incidence was 0.640 (95% CI 0.628, 0.652), but this does not tell us about the ability of the TyG index to capture a treatment effect. A high AUC for predicting primary outcome does not necessarily mean that the marker can replace the primary outcome in a future study and be used to make inference about the treatment effect on the primary outcome. In addition, the TyG index is a function of serum triglyceride, which is often considered to be a highly sensitive lifestyle measure that is influenced by factors such as alcohol intake and medications such as beta-blockers, corticosteroids, and estrogens.<xref rid="R31" ref-type="bibr">31</xref> The potential influence of such factors, or especially any changes in these lifestyle factors, on the TyG index over time may hinder the utility of the TyG index as a surrogate marker and possibly lower the PTE of this marker.</p>
              <p>The PTE is a popular measure for surrogacy evaluation, but is also frequently criticized.<xref rid="R20" ref-type="bibr">20 32</xref> In the past, the tendency has been to estimate the PTE using a simple regression model framework, where a regression model is first fit with only the treatment indicator in the model and then a second model is fit adding in the surrogate marker.<xref rid="R12" ref-type="bibr">12</xref> The PTE is estimated by looking at how much the regression coefficient for treatment changed when the surrogate marker was added to the model. The fundamental problem with this approach is that it is only valid if these two regression models hold. In practice, it is almost impossible to correctly specify models to describe clinical data. Furthermore, in the censored outcome setting where Cox proportional hazards models are used for the analysis, it is known that all relevant model assumptions cannot simultaneously hold in most cases.<xref rid="R19" ref-type="bibr">19</xref> Using such a model-based approach can result in substantial bias in the estimate of the PTE.<xref rid="R19" ref-type="bibr">19 21</xref> Non-parametric methods used in this analysis do not assume any model specification and thus do not have this disadvantage. However, non-parametric methods generally require a large sample size and are not feasible to use in small sample data sets. Future statistical work is needed to develop robust methods that can be used when the sample size is small.</p>
              <p>The ability to use a surrogate marker to evaluate a treatment effect earlier or with less cost is the ultimate goal of surrogate evaluation. While we focus on the surrogate information at 1 year, our approach could similarly be used to examine the PTE of surrogate information at year 2 or 3 when <italic toggle="yes">t</italic>=4 years. In addition, there are parallel model-free methods to investigate whether this earlier information can achieve a similar power as the study based on diabetes incidence at year 4, which would then suggest a shorter clinical trial duration is possible. However, using an invalid surrogate marker to make a decision about a treatment effect can have dire consequences. One could conclude a treatment effect when there truly is no treatment effect on the primary outcome, or vice versa conclude there is no treatment effect when there truly is one. The most worrisome concern is the possibility of the so-called surrogate paradox, where the treatment has a positive treatment effect on the surrogate marker, but a negative treatment effect on the primary outcome.<xref rid="R20" ref-type="bibr">20 33</xref> Strong statistical assumptions are needed to ensure that this situation does not occur. Evaluating a surrogate marker using data from a randomized trial, as we have done in this study, lessens (but does not eliminate) the number of assumptions that are needed; evaluating a surrogate marker using observational data is much more difficult as there is no longer balance between the treatment groups at baseline.</p>
              <p>Although HbA1c is the only surrogate marker listed for type 2 diabetes in the FDA’s current table of surrogate markers/endpoints, our results found that both glucose and HOMA-IR explained more of the treatment effect on diabetes incidence than did HbA1c.<xref rid="R4" ref-type="bibr">4</xref> Interestingly, for individuals at high risk for diabetes, treatments aimed at preventing or delaying a diabetes diagnosis often no longer even attempt to promise effectiveness with respect to actually preventing diabetes, but instead directly market their effectiveness on a surrogate itself, such as glucose or HbA1c. This marketing practice can be dangerous as it implies that individuals eligible to take the medication are likely making the causal association on their own, for example, “if I take this drug and I lower my glucose, then I will be less likely to be diagnosed with diabetes.”</p>
              <p>An important area for future work is the examination of potential heterogeneity in the utility of a surrogate marker.<xref rid="R34" ref-type="bibr">34</xref> That is, a biomarker may be a valid surrogate marker for certain subpopulations, but not others. Park <italic toggle="yes">et al</italic><xref rid="R8" ref-type="bibr">8</xref> conducted a population-based cohort study from the Korean Genome and Epidemiology and compared the predictive ability of the TyG index and HOMA-IR. They found that the TyG index was a better predictor of incident diabetes than HOMA-IR and hypothesize that this may be attributable to the high glycemic index characteristics of the Korean diet and the dual dimensions of the TyG index. Specifically, while HOMA-IR reflects hepatic insulin resistance, the TyG index is thought to reflect the insulin resistance of both the adipose and hepatic tissues, resulting in the TyG index being superior in predicting diabetes incidence, particularly in Koreans who prefer to consume high glycemic index foods. In addition, previous work has demonstrated lower pancreatic volume, higher pancreatic fat content, and lower HOMA-IR among healthy Koreans compared with a matched sample of healthy white individuals.<xref rid="R35" ref-type="bibr">35</xref> It is unknown whether similar heterogeneity may exist with respect to surrogacy for these markers. For example, it is possible that the PTE for TyG index and/or HOMA-IR may be different for different subpopulations. Unfortunately, the racial/ethnic composition of the DPP study does not allow us to examine this, but future work is needed to explore surrogate heterogeneity, particularly in Asian populations.</p>
              <p>For a surrogate marker to gain clinical acceptance as a valid surrogate marker for a particular outcome, multiple studies with different patient populations and using different types of analyses are often needed. Given the potential consequences of using an invalid surrogate, results from a single study are simply not enough. Unfortunately, while a plethora of clinical trials are constantly in progress, it is often difficult to gain access to data from these clinical trials. Thus, it is essential to emphasize the importance of data sharing and data access for the purpose of furthering surrogate marker research and evaluation.</p>
              <p>Our study has some limitations. First, the DPP participant population is not necessarily generalizable to the general population, and thus our results are not generalizable, particularly to populations with different racial/ethnic compositions. This is particularly relevant in surrogate marker research because concerns about transportability of surrogate information from one study to a future study may impact a decision to use the surrogate marker in a future study to test for a treatment effect. In addition, none of the examined markers explained a sufficiently high proportion (eg, over 0.90) of the treatment effect and thus the results from this study do not necessarily support replacing diabetes incidence with change in any of these markers in a future study. Despite these limitations, this study is the first to compare these five surrogate markers using a robust model-free approach, and these results provide insight into the complex relationship between the change in these markers and diabetes incidence that may be useful for future studies in diabetes prevention.</p>
            </sec>
          </body>
          <back>
            <ack>
              <p>The Diabetes Prevention Program (DPP) was conducted by the DPP Research Group and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the General Clinical Research Center Program, the National Institute of Child Health and Human Development (NICHD), the National Institute on Aging (NIA), the Office of Research on Women’s Health, the Office of Research on Minority Health, the Centers for Disease Control and Prevention (CDC), and the American Diabetes Association. The data from the DPP were supplied by the NIDDK Central Repository.</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> LP, LT, TC, and LPP were involved in the conception, design, and conduct of the study and in the analysis and interpretation of the results. LP wrote the first draft of the manuscript, and LT, TC, and LPP edited, reviewed, and approved the final version of the manuscript. LP is the guarantor of this work and as such had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. LP, LT, TC, and LPP substantially contributed to the revision during peer review.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> Support for this research was provided by the National Institutes of Health (grant R01DK118354).</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Disclaimer:</bold> This manuscript was not prepared under the auspices of the DPP and does not represent analyses or conclusions of the DPP Research Group, the NIDDK Central Repository, or the NIH.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> None declared.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p>
              </fn>
            </fn-group>
            <sec sec-type="data-availability">
              <title>Data availability statement</title>
              <p>Data are available in a public, open access repository. This secondary data analysis is based on publicly available data through the NIDDK Central Repository.</p>
            </sec>
            <sec sec-type="ethics-statement">
              <title>Ethics statements</title>
              <sec>
                <title>Patient consent for publication</title>
                <p content-type="ethics-consent-to-publish">Not required.</p>
              </sec>
              <sec>
                <title>Ethics approval</title>
                <p content-type="ethics-approval">The University of Texas at Austin Institutional Review Board reviewed this study and determined that it was not research involving human subjects as defined by DHHS and FDA regulations; the activity was determined to be secondary use of de-identified data (no direct or links to identifiers).</p>
              </sec>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>FDA</collab></person-group>. <article-title>Accelerated approval</article-title>. <comment>Available</comment>: <uri xlink:href="https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval">https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval</uri> [Accessed <comment>20 Apr 2023</comment>].</mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mahase</surname><given-names>E</given-names></string-name></person-group>. <article-title>FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway</article-title>. <source>BMJ</source><year>2021</year>:<fpage>1898</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.n1898</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rizk</surname><given-names>JG</given-names></string-name>, <string-name><surname>Lewin</surname><given-names>JC</given-names></string-name></person-group>. <article-title>FDA’s dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps</article-title>. <source>BMJ Evid Based Med</source><year>2023</year>;<volume>28</volume>:<fpage>78</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1136/bmjebm-2022-111914</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>FDA</collab></person-group>. <article-title>Table of Surrogate endpoints that were the basis of drug approval or licensure</article-title>. <comment>Available</comment>: <uri xlink:href="https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure">https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure</uri> [Accessed <comment>20 Apr 2023</comment>].</mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bennett</surname><given-names>CM</given-names></string-name>, <string-name><surname>Guo</surname><given-names>M</given-names></string-name>, <string-name><surname>Dharmage</surname><given-names>SC</given-names></string-name></person-group>. <article-title>Hba1C as a screening tool for detection of type 2 diabetes: a systematic review</article-title>. <source>Diabet Med</source><year>2007</year>;<volume>24</volume>:<fpage>333</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1111/j.1464-5491.2007.02106.x</pub-id><pub-id pub-id-type="pmid">17367307</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ko</surname><given-names>GT</given-names></string-name>, <string-name><surname>Chan</surname><given-names>JC</given-names></string-name>, <string-name><surname>Yeung</surname><given-names>VT</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Combined use of a fasting plasma glucose concentration and HbA1C or Fructosamine predicts the likelihood of having diabetes in high-risk subjects</article-title>. <source>Diabetes Care</source><year>1998</year>;<volume>21</volume>:<fpage>1221</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.2337/diacare.21.8.1221</pub-id><pub-id pub-id-type="pmid">9702423</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Navarro-González</surname><given-names>D</given-names></string-name>, <string-name><surname>Sánchez-Íñigo</surname><given-names>L</given-names></string-name>, <string-name><surname>Pastrana-Delgado</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Triglyceride–glucose index (Tyg index) in comparison with fasting plasma glucose improved diabetes prediction in patients with normal fasting glucose: the vascular-metabolic CUN cohort</article-title>. <source>Preventive Medicine</source><year>2016</year>;<volume>86</volume>:<fpage>99</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1016/j.ypmed.2016.01.022</pub-id><pub-id pub-id-type="pmid">26854766</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname><given-names>HM</given-names></string-name>, <string-name><surname>Lee</surname><given-names>HS</given-names></string-name>, <string-name><surname>Lee</surname><given-names>Y-J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The triglyceride-glucose index is a more powerful Surrogate marker for predicting the prevalence and incidence of type 2 diabetes mellitus than the Homeostatic model assessment of insulin resistance</article-title>. <source>Diabetes Res Clin Pract</source><year>2021</year>;<volume>180</volume>:<fpage>109042</fpage>. <pub-id pub-id-type="doi">10.1016/j.diabres.2021.109042</pub-id><pub-id pub-id-type="pmid">34506839</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Low</surname><given-names>S</given-names></string-name>, <string-name><surname>Khoo</surname><given-names>KCJ</given-names></string-name>, <string-name><surname>Irwan</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The role of triglyceride glucose index in development of type 2 diabetes mellitus</article-title>. <source>Diabetes Res Clin Pract</source><year>2018</year>;<volume>143</volume>:<fpage>43</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.diabres.2018.06.006</pub-id><pub-id pub-id-type="pmid">29936253</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name><surname>Parast</surname><given-names>L</given-names></string-name>, <string-name><surname>Gilbert</surname><given-names>P</given-names></string-name>, <string-name><surname>Wu</surname><given-names>L</given-names></string-name></person-group>. <article-title>Statistical challenges in the identification, validation, and use of surrogate markers. Banff International research station for mathematical innovation and discovery</article-title>. <year>2022</year>. <comment>Available</comment>: <uri xlink:href="https://www.birs.ca/cmo-workshops/2022/22w5184/report22w5184.pdf">https://www.birs.ca/cmo-workshops/2022/22w5184/report22w5184.pdf</uri></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Prentice</surname><given-names>RL</given-names></string-name></person-group>. <article-title>Surrogate endpoints in clinical trials: definition and operational criteria</article-title>. <source>Stat Med</source><year>1989</year>;<volume>8</volume>:<fpage>431</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1002/sim.4780080407</pub-id><pub-id pub-id-type="pmid">2727467</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Freedman</surname><given-names>LS</given-names></string-name>, <string-name><surname>Graubard</surname><given-names>BI</given-names></string-name>, <string-name><surname>Schatzkin</surname><given-names>A</given-names></string-name></person-group>. <article-title>Statistical validation of intermediate endpoints for chronic diseases</article-title>. <source>Stat Med</source><year>1992</year>;<volume>11</volume>:<fpage>167</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1002/sim.4780110204</pub-id><pub-id pub-id-type="pmid">1579756</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>JMG</given-names></string-name></person-group>. <article-title>A measure of the proportion of treatment effect explained by a surrogate marker</article-title>. <source>Biometrics</source><year>2002</year>;<volume>58</volume>:<fpage>803</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1111/j.0006-341x.2002.00803.x</pub-id><pub-id pub-id-type="pmid">12495134</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Frangakis</surname><given-names>CE</given-names></string-name>, <string-name><surname>Rubin</surname><given-names>DB</given-names></string-name></person-group>. <article-title>Principal stratification in causal inference</article-title>. <source>Biometrics</source><year>2002</year>;<volume>58</volume>:<fpage>21</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/j.0006-341x.2002.00021.x</pub-id><pub-id pub-id-type="pmid">11890317</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Elliott</surname><given-names>MR</given-names></string-name></person-group>. <article-title>Surrogate endpoints in clinical trials</article-title>. <source>Annu Rev Stat Appl</source><year>2023</year>;<volume>10</volume>:<fpage>75</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-statistics-032921-035359</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Conlon</surname><given-names>ASC</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>JMG</given-names></string-name>, <string-name><surname>Elliott</surname><given-names>MR</given-names></string-name></person-group>. <article-title>Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal</article-title>. <source>Biostatistics</source><year>2014</year>;<volume>15</volume>:<fpage>266</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1093/biostatistics/kxt051</pub-id><pub-id pub-id-type="pmid">24285772</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Agyemang</surname><given-names>E</given-names></string-name>, <string-name><surname>Magaret</surname><given-names>AS</given-names></string-name>, <string-name><surname>Selke</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Herpes simplex virus shedding rate: surrogate outcome for genital herpes recurrence frequency and lesion rates, and phase 2 clinical trials end point for evaluating efficacy of antivirals</article-title>. <source>J Infect Dis</source><year>2018</year>;<volume>218</volume>:<fpage>1691</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiy372</pub-id><pub-id pub-id-type="pmid">30020484</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sprenger</surname><given-names>T</given-names></string-name>, <string-name><surname>Kappos</surname><given-names>L</given-names></string-name>, <string-name><surname>Radue</surname><given-names>E-W</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide</article-title>. <source>Mult Scler</source><year>2020</year>;<volume>26</volume>:<fpage>1207</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1177/1352458519855722</pub-id><pub-id pub-id-type="pmid">31198103</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname><given-names>DY</given-names></string-name>, <string-name><surname>Fleming</surname><given-names>TR</given-names></string-name>, <string-name><surname>De Gruttola</surname><given-names>V</given-names></string-name></person-group>. <article-title>Estimating the proportion of treatment effect explained by a surrogate marker</article-title>. <source>Stat Med</source><year>1997</year>;<volume>16</volume>:<fpage>1515</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1002/(sici)1097-0258(19970715)16:13&lt;1515::aid-sim572&gt;3.0.co;2-1</pub-id><pub-id pub-id-type="pmid">9249922</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vanderweele</surname><given-names>TJ</given-names></string-name></person-group>. <article-title>Surrogate measures and consistent surrogates</article-title>. <source>Biometrics</source><year>2013</year>;<volume>69</volume>:<fpage>561</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/biom.12071</pub-id><pub-id pub-id-type="pmid">24073861</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Parast</surname><given-names>L</given-names></string-name>, <string-name><surname>McDermott</surname><given-names>MM</given-names></string-name>, <string-name><surname>Tian</surname><given-names>L</given-names></string-name></person-group>. <article-title>Robust estimation of the proportion of treatment effect explained by surrogate marker information</article-title>. <source>Stat Med</source><year>2016</year>;<volume>35</volume>:<fpage>1637</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1002/sim.6820</pub-id><pub-id pub-id-type="pmid">26631934</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Parast</surname><given-names>L</given-names></string-name>, <string-name><surname>Cai</surname><given-names>T</given-names></string-name>, <string-name><surname>Tian</surname><given-names>L</given-names></string-name></person-group>. <article-title>Evaluating surrogate marker information using censored data</article-title>. <source>Stat Med</source><year>2017</year>;<volume>36</volume>:<fpage>1767</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1002/sim.7220</pub-id><pub-id pub-id-type="pmid">28088843</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name><surname>Parast</surname><given-names>L</given-names></string-name>, <string-name><surname>Tian</surname><given-names>LU</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Model-free approach to quantifying the proportion of treatment effect explained by a surrogate marker</article-title>. <source>Biometrika</source><year>2020</year>;<volume>107</volume>:<fpage>107</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1093/biomet/asz065</pub-id><pub-id pub-id-type="pmid">32587413</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The Diabetes Prevention Program Research Group</collab></person-group>. <article-title>The diabetes prevention program: design and methods for a clinical trial in the prevention of type 2 diabetes</article-title>. <source>Diabetes Care</source><year>1999</year>;<volume>22</volume>:<fpage>623</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.2337/diacare.22.4.623</pub-id><pub-id pub-id-type="pmid">10189543</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Group</surname><given-names>DPPR</given-names></string-name></person-group>. <article-title>Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin</article-title>. <source>N Engl J Med</source><year>2002</year>;<volume>346</volume>:<fpage>393</fpage>–<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa012512</pub-id><pub-id pub-id-type="pmid">11832527</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>NIDDK Central Repository</collab></person-group>. <article-title>Diabetes prevention program (DPP)</article-title>. <comment>Available</comment>: <uri xlink:href="https://repository.niddk.nih.gov/studies/dpp/">https://repository.niddk.nih.gov/studies/dpp/</uri> [Accessed <comment>20 Apr 2023</comment>].</mixed-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kaplan</surname><given-names>EL</given-names></string-name>, <string-name><surname>Meier</surname><given-names>P</given-names></string-name></person-group>. <article-title>Nonparametric estimation from incomplete observations</article-title>. <source>Journal of the American Statistical Association</source><year>1958</year>;<volume>53</volume>:<fpage>457</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1080/01621459.1958.10501452</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>C-FJ</given-names></string-name></person-group>. <article-title>Jackknife, Bootstrap and other resampling methods in regression analysis</article-title>. <source>Ann Stat</source><year>1986</year>;<volume>14</volume>:<fpage>1261</fpage>–<lpage>95</lpage>.</mixed-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wei</surname><given-names>L</given-names></string-name></person-group>. <article-title>Estimating subject‐specific survival functions under the accelerated failure time model</article-title>. <source>Biometrika</source><year>2003</year>;<volume>90</volume>:<fpage>717</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1093/biomet/90.3.717</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <mixed-citation publication-type="webpage"><article-title>Rsurrogate: robust estimation of the proportion of treatment effect explained by surrogate marker information</article-title>. <comment>Available</comment>: <uri xlink:href="https://cran.r-project.org/web/packages/Rsurrogate/">https://cran.r-project.org/web/packages/Rsurrogate/</uri> [Accessed <comment>5 May 2023</comment>].</mixed-citation>
              </ref>
              <ref id="R31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goldberg</surname><given-names>RB</given-names></string-name>, <string-name><surname>Chait</surname><given-names>A</given-names></string-name></person-group>. <article-title>A comprehensive update on the chylomicronemia syndrome</article-title>. <source>Front Endocrinol (Lausanne)</source><year>2020</year>;<volume>11</volume>:<elocation-id>593931</elocation-id>. <pub-id pub-id-type="doi">10.3389/fendo.2020.593931</pub-id><pub-id pub-id-type="pmid">33193106</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wolfson</surname><given-names>J</given-names></string-name>, <string-name><surname>Gilbert</surname><given-names>P</given-names></string-name></person-group>. <article-title>Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials</article-title>. <source>Biometrics</source><year>2010</year>;<volume>66</volume>:<fpage>1153</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1111/j.1541-0420.2009.01380.x</pub-id><pub-id pub-id-type="pmid">20105158</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Elliott</surname><given-names>MR</given-names></string-name>, <string-name><surname>Conlon</surname><given-names>ASC</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Surrogacy marker paradox measures in meta-analytic settings</article-title>. <source>Biostatistics</source><year>2015</year>;<volume>16</volume>:<fpage>400</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1093/biostatistics/kxu043</pub-id><pub-id pub-id-type="pmid">25236906</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Parast</surname><given-names>L</given-names></string-name>, <string-name><surname>Cai</surname><given-names>T</given-names></string-name>, <string-name><surname>Tian</surname><given-names>L</given-names></string-name></person-group>. <article-title>Testing for heterogeneity in the utility of a surrogate marker</article-title>. <source>Biometrics</source><year>2023</year>;<volume>79</volume>:<fpage>799</fpage>–<lpage>810</lpage>. <pub-id pub-id-type="doi">10.1111/biom.13600</pub-id><pub-id pub-id-type="pmid">34874550</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roh</surname><given-names>E</given-names></string-name>, <string-name><surname>Kim</surname><given-names>KM</given-names></string-name>, <string-name><surname>Park</surname><given-names>KS</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Comparison of pancreatic volume and fat amount linked with glucose homeostasis between healthy Caucasians and Koreans</article-title>. <source>Diabetes Obes Metab</source><year>2018</year>;<volume>20</volume>:<fpage>2642</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1111/dom.13447</pub-id><pub-id pub-id-type="pmid">29934972</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
